Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabozantinib S-Malate

FDA-approved product (capsule, oral), marketed as Cabometyx, Cabozantinib S-Malate, Cometriq.

Registered studies
45
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Cabozantinib S-Malate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Clear cell renal carcinoma
  • Hepatocellular carcinoma
  • Neoplasm
  • Papillary renal cell carcinoma
  • Papillary thyroid carcinoma
  • Renal cell carcinoma
  • Thyroid cancer
  • Thyroid carcinoma
  • Thyroid neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

45registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabozantinib S-Malate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabozantinib S-Malate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

    NCT04339738 · start 2020-11-04

    Registered record
    Registry ID
    NCT04339738
    Conditions
    Skin Angiosarcoma; Skin Radiation-Related Angiosarcoma; Visceral Angiosarcoma
    Interventions
    Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; FDG-Positron Emission Tomography; Magnetic Resonance Imaging; Nivolumab; Paclitaxel; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-11-04
    Completion
    2027-01-21
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Angiosarcoma; Skin Radiation-Related Angiosarcoma; Visceral Angiosarcoma
    InterventionBiospecimen Collection; Cabozantinib S-malate; Computed Tomography; FDG-Positron Emission Tomography +5 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

    NCT04079712 · start 2020-08-06

    Registered record
    Registry ID
    NCT04079712
    Conditions
    Metastatic Large Cell Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Metastatic Neuroendocrine Neoplasm; Metastatic Small Cell Neuroendocrine Carcinoma
    Interventions
    Cabozantinib S-malate; Ipilimumab; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-08-06
    Completion
    2026-08-19
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Large Cell Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Metastatic Neuroendocrine Neoplasm; Metastatic Small Cell Neuroendocrine Carcinoma
    InterventionCabozantinib S-malate; Ipilimumab; Nivolumab
    PhasePhase 2
    Registry statusActive not recruiting

  • Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

    NCT04071223 · start 2020-07-29

    Registered record
    Registry ID
    NCT04071223
    Conditions
    Advanced Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Collecting Duct Carcinoma; Kidney Medullary Carcinoma; Metastatic Malignant Neoplasm in the Bone; Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma
    Interventions
    Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Questionnaire Administration; Radium Ra 223 Dichloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-07-29
    Completion
    2026-10-01
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Collecting Duct Carcinoma +5 more
    InterventionBiospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography +4 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

    NCT04310007 · start 2020-07-13

    Registered record
    Registry ID
    NCT04310007
    Conditions
    Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
    Interventions
    Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Docetaxel; Echocardiography Test; Gemcitabine Hydrochloride; Nab-paclitaxel; Nivolumab; Paclitaxel; Ramucirumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-07-13
    Completion
    2026-12-31
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
    InterventionBiospecimen Collection; Cabozantinib S-malate; Computed Tomography; Docetaxel +6 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

    NCT04220229 · start 2020-06-01

    Registered record
    Registry ID
    NCT04220229
    Conditions
    Sarcoma of the Extremity; Stage I Soft Tissue Sarcoma of the Trunk and Extremities; Stage IA Soft Tissue Sarcoma of the Trunk and Extremities; Stage IB Soft Tissue Sarcoma of the Trunk and Extremities; Stage II Soft Tissue Sarcoma of the Trunk and Extremities
    Interventions
    Cabozantinib S-malate; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2020-06-01
    Completion
    2024-10-31
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma of the Extremity; Stage I Soft Tissue Sarcoma of the Trunk and Extremities; Stage IA Soft Tissue Sarcoma of the Trunk and Extremities; Stage IB Soft Tissue Sarcoma of the Trunk and Extremities +1 more
    InterventionCabozantinib S-malate; Radiation Therapy
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

    NCT03914300 · start 2020-02-10

    Registered record
    Registry ID
    NCT03914300
    Conditions
    Differentiated Thyroid Gland Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma; Refractory Thyroid Gland Carcinoma; Tall Cell Variant Thyroid Gland Papillary Carcinoma; Thyroid Gland Follicular Carcinoma; Thyroid Gland Oncocytic Carcinoma; Thyroid Gland Papillary Carcinoma
    Interventions
    Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-02-10
    Completion
    2026-12-17
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDifferentiated Thyroid Gland Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma +5 more
    InterventionBiospecimen Collection; Cabozantinib S-malate; Computed Tomography; Ipilimumab +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Cabozantinib in Advanced Adrenocortical Carcinoma

    NCT03612232 · start 2019-06-04

    Registered record
    Registry ID
    NCT03612232
    Conditions
    Adrenocortical Carcinoma
    Interventions
    Cabozantinib-s-malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-06-04
    Completion
    2025-04-30
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdrenocortical Carcinoma
    InterventionCabozantinib-s-malate
    PhasePhase 2
    Registry statusUnknown

  • Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    NCT03866382 · start 2019-05-13

    Registered record
    Registry ID
    NCT03866382
    Conditions
    Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Neuroendocrine Carcinoma; Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Collecting Duct Carcinoma; Invasive Bladder Giant Cell Urothelial Carcinoma; Invasive Bladder Lymphoepithelioma-Like Carcinoma; Invasive Bladder Nested Urothelial Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Bladder Urothelial Carcinoma; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Malignant Testicular Leydig Cell Tumor; Malignant Testicular Sertoli Cell Tumor; Metastatic Bladder Carcinoma; Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma; Metastatic Bladder Giant Cell Urothelial Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Lipid-Rich Urothelial Carcinoma; Metastatic Bladder Micropapillary Urothelial
    Interventions
    Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2019-05-13
    Completion
    2027-02-28
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Neuroendocrine Carcinoma +20 more
    InterventionBiospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography +5 more
    PhasePhase 2
    Registry statusRecruiting

  • Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

    NCT03375320 · start 2018-10-26

    Registered record
    Registry ID
    NCT03375320
    Conditions
    Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1; Locally Advanced Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Neuroendocrine Tumor; Lung Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Lung Neuroendocrine Neoplasm; Metastatic Lung Neuroendocrine Tumor; Metastatic Pancreatic Neuroendocrine Neoplasm; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymus Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Neuroendocrine Tumor; Neuroendocrine Tumor G2; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Thymus Neuroendocrine Tumor
    Interventions
    Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Placebo Administration; Quality-of-Life Assessment; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2018-10-26
    Completion
    2026-08-19
    Enrolment
    298

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFunctioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1 +19 more
    InterventionBiospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging +3 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

    NCT03468985 · start 2018-05-07

    Registered record
    Registry ID
    NCT03468985
    Conditions
    Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7
    Interventions
    Cabozantinib; Ipilimumab; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-05-07
    Completion
    2022-12-21
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7
    InterventionCabozantinib; Ipilimumab; Nivolumab
    PhasePhase 2
    Registry statusCompleted

  • Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

    NCT03367741 · start 2018-04-16

    Registered record
    Registry ID
    NCT03367741
    Conditions
    Advanced Endometrial Carcinoma; Metastatic Endometrial Carcinoma; Recurrent Endometrial Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
    Interventions
    Biopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-04-16
    Completion
    2027-07-23
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Endometrial Carcinoma; Metastatic Endometrial Carcinoma; Recurrent Endometrial Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 +1 more
    InterventionBiopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

    NCT02867592 · start 2017-05-18

    Registered record
    Registry ID
    NCT02867592
    Conditions
    Adrenal Cortical Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Tissue; Clear Cell Sarcoma of Soft Tissue; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; Osteosarcoma; Recurrent Adrenal Cortical Carcinoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Clear Cell Sarcoma of Soft Tissue; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Kidney Wilms Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Primary Malignant Central Nervous System Neoplasm; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Medullary Carcinoma; Refractory Adrenal Cortical Carcinoma; Refractory Alveolar Soft Part Sarcoma; Refractory Clear Cell Sarcoma of Soft Tissue; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Ost
    Interventions
    Cabozantinib; Cabozantinib S-malate; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-05-18
    Completion
    2027-06-28
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdrenal Cortical Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Tissue +27 more
    InterventionCabozantinib; Cabozantinib S-malate; Pharmacological Study
    PhasePhase 2
    Registry statusActive not recruiting

  • Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

    NCT02761057 · start 2016-07-25

    Registered record
    Registry ID
    NCT02761057
    Conditions
    Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
    Interventions
    Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Crizotinib; Savolitinib; Sunitinib Malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-07-25
    Completion
    2023-10-19
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7 +3 more
    InterventionBiospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography +3 more
    PhasePhase 2
    Registry statusCompleted

  • Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

    NCT02592356 · start 2015-11-16

    Registered record
    Registry ID
    NCT02592356
    Conditions
    Differentiated Thyroid Gland Carcinoma; Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Thyroid Gland Medullary Carcinoma
    Interventions
    Computed Tomography; Dual X-ray Absorptiometry; Physical Examination; Quality-of-Life Assessment; Questionnaire Administration; Cabozantinib; Lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-11-16
    Completion
    2024-03-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDifferentiated Thyroid Gland Carcinoma; Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Thyroid Gland Medullary Carcinoma
    InterventionComputed Tomography; Dual X-ray Absorptiometry; Physical Examination; Quality-of-Life Assessment +3 more
    PhaseNot applicable
    Registry statusCompleted

  • Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

    NCT02496208 · start 2015-07-22

    Registered record
    Registry ID
    NCT02496208
    Conditions
    Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Sarcomatoid Urothelial Carcinoma; Kidney Medullary Carcinoma; Malignant Genitourinary System Neoplasm; Malignant Solid Neoplasm; Penile Carcinoma; Penile Squamous Cell Carcinoma; Renal Cell Carcinoma; Renal Pelvis Urothelial Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8
    Interventions
    Biopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2015-07-22
    Completion
    2026-09-30
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma +24 more
    InterventionBiopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography +4 more
    PhasePhase 1
    Registry statusActive not recruiting